Journal of Dali University ›› 2023, Vol. 8 ›› Issue (2): 51-55.

Previous Articles     Next Articles

Study of the Distribution of High-Risk Human Papilloma Virus Subtypes in Liangshan Region, Sichuan Province

Chen Huaqiu1, Chen Xingyou2, Wang Guangming3*   

  1. (1. Department of Laboratory, Xichang People's Hospital, Xichang, Sichuan 615000, China; 2. Department of Pathology, Xichang People's Hospital, Xichang, Sichuan 615000, China; 3. Gene Testing Center, The First Affiliated Hospital of Dali University, Dali, Yunnan 671000, China)

  • Received:2022-04-05 Revised:2022-06-14 Online:2023-02-15 Published:2023-03-02

Abstract: Objective: To understand the characteristics of high-risk human papillomavirus (HR-HPV) infection among women in Liangshan Region, Sichuan Province, and to provide data support for the development and application of HPV vaccine in this area.Methods: The PCR fluorescence probe method was used to detect HR-HPV in 7 445 women who visited the physical examination center of Xichang People's Hospital and the outpatient department of obstetrics and gynecology from November 14,2018 to December 30,2020, and the detection results were statistically analyzed. Results:Among the 7 445 samples, 1 027 were HR-HPV positive, with a positive rate of 13.79%, and all 15 HR-HPV subtypes were detected. Among them, 818 cases (79.65%) were single infection, and 209 cases (20.35%) were multiple infection. The top three subtypes of HR-HPV infection were HPV 52, 16 and 53. In all age groups, the positive rate of subjects aged ≥ 61 years was the highest (22.39%), followed by subjects aged 21-30 years (15.86%). Conclusion: The distribution of HR-HPV subtype infection in Liangshan Region, Sichuan Province has certain regional characteristics, and the positive rate is the highest among people over 61 years old. Therefore, it is necessary to strengthen the publicity of HR-HPV screening among the suitable age population.

Key words: font-family:Times New Roman, ">high-risk human papilloma virusfont-family:Times New Roman, ">, font-family:Times New Roman, "> PCR fluorescence probe methodfont-family:Times New Roman, ">, font-family:Times New Roman, "> cervical carcinoma

CLC Number: